Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Patient Access Pulse by Pelitas: Engaging iPAS Version 10 for Interoperability

As healthcare revolutionizes to meet interoperability needs, so does the technology. iPAS Version 10 (v10) is one data management tool driving the transformation. Kristine Anderson, Vice President of Solutions Management at Pelitas, and Tracy Eckerman, Associate Vice President of Technical Solutions Management, met with host Tyler Kern to explain exactly how. The pandemic accelerated tech…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

As healthcare revolutionizes to meet interoperability needs, so does the technology. iPAS Version 10 (v10) is one data management tool driving the transformation. Kristine Anderson, Vice President of Solutions Management at Pelitas, and Tracy Eckerman, Associate Vice President of Technical Solutions Management, met with host Tyler Kern to explain exactly how.

The pandemic accelerated tech too creation to meet various healthcare needs, such as patient access, telehealth, and virtual intake. The virtual intake medicine suite was one of the first products iPAS v10 launched; it involves the patient so they are an active participant in their care management.

While helpful, the variety of tools has presented challenges, creating siloed data if not properly integrated. “Interoperability is going to be absolutely critical in this next year for being able to leverage all of those tools,” explained Eckerman. Next year, the plan is to deepen integration opportunities. “It’s really going to be exciting to build on what we’ve already done and take the product to the next level,” said Anderson.

Anderson provided the definition of data management, stating that it is “the practice of collecting, keeping, and using data securely, cost-effectively, and efficiently.’” Collecting data seems basic, but what data needs to be collected varies by patient. It must be stored in the EHR without extra steps and used effectively to easily manipulated reports that track trends.

Looking forward, where does the ultimate answer in healthcare data management lie? “Digital transformation maturity doesn’t happen overnight but getting the right data in the right system and working with the right people will drive organizational transformation and help our clients improve their business processes in patient access,” Eckerman summarized.

Head to pelitas.com for insight into iPAS v10 and subscribe to Patient Access Pulse to keep up with the latest topics

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512